...
首页> 外文期刊>Journal of Nanobiotechnology >Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system preparation and in vitro/in vivo characterization
【24h】

Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system preparation and in vitro/in vivo characterization

机译:基于有机粘土囊泡的三元纳米复合载体作为有效的结肠靶向药物递送体系制备和体内/体内表征

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This study aimed to develop a new colon-targeted drug delivery system via the preparation of ternary nanocomposite carriers based on organic polymer, aminoclay and lipid vesicles. Budesonide (Bud), an anti-inflammatory drug was chosen as a model drug and encapsulated into three different formulations: liposome (Bud-Lip), aminoclay-coated liposome (AC-Bud-Lip), and Eudragit S100-aminoclay double coated liposome (EAC-Bud-Lip). The formation of the aminoclay-lipid vesicle nanocomposite was confirmed by energy dispersive X-ray spectrum, transmission electron microscopy, and Fourier-transform infrared spectroscopy. All formulations were produced with a high encapsulation efficiency in a narrow size distribution. Drug release from EAC-Bud-Lip was approximately 10% for 2-h incubation at pH 1.2, implying the minimal drug release in acidic gastric condition. At pH 7.4, EAC-Bud-Lip underwent significant size reduction and exhibited drug release profiles similar to that from AC-Bud-Lip, implying the pH-dependent removal of the outer coating layer. Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF- and IL-6 secretion in LPS-stimulated Raw264.7 cells. Furthermore, a bio-distribution study in mice demonstrated that Eudragit S100-aminoclay dual coating led to a higher colonic distribution with a longer residence time, which correlated well with the delayed systemic drug exposure in rats. Taken together, the present study suggests that the ternary nanocomposite carrier consisting of Eudragit S100, aminoclay, and lipid vesicle might be useful as an effective colon-targeted drug delivery system.
机译:本研究旨在通过基于有机聚合物,氨基粘土和脂质囊泡制备三元纳米复合载体来开发新的结肠靶向药物输送系统。蛋白质(芽),选择一种抗炎药作为模型药物,包封成三种不同的配方:脂质体(芽唇),氨基粘土涂覆的脂质体(AC-芽唇),以及Eudragit S100-aminoclay双涂层脂质体(EAC-芽唇)。通过能量分散X射线谱,透射电子显微镜和傅里叶变换红外光谱证实了氨基酰胺 - 脂质囊泡纳米复合物的形成。所有制剂在窄尺寸分布中以高封装效率生产。从EAC-芽唇中的药物释放约为2-H pH 1.2孵育的10%,暗示酸性胃病症中的最小药物释放。在pH 7.4中,EAC-BUD-LIP经历了显着的尺寸减小,并且表现出类似于来自AC-芽唇的药物释放曲线,暗示外涂层的pH依赖性除去。与自由芽溶液相比,EAC-芽唇在CaCO-2细胞中取得了更高的药物吸收,并在LPS刺激的Raw264.7细胞中表现出较强的TNF和IL-6分泌。此外,小鼠的生物分布研究证明,Eudragit S100-aminoclay双涂层导致具有较长的停留时间的结肠分布,其停留时间较好,随着大鼠延迟的全身药物暴露良好。在一起,本研究表明,由Eudragit S100,Aminoclay和脂质囊泡组成的三元纳米复合材料载体可能是有效的结肠靶向药物递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号